OncoMatch/Clinical Trials/NCT06719700
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Is NCT06719700 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chemotherapy and Immunotherapy for toripalimab.
Treatment: Chemotherapy · Immunotherapy · Angio-immuno kinase inhibitor · Consolidation Therapy with Toripalimab and Surufatinib — Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage I, II, III
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Previous Anti-PD-1/PD-L1 Therapy: Prior use of any anti-PD-1 or anti-PD-L1 antibodies.
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5 × 10⁹/L. Platelet count ≥100 × 10⁹/L. Hemoglobin ≥9.0 g/dL.
Kidney function
Calculated creatinine clearance ≥50 mL/min using the Cockcroft-Gault formula.
Liver function
Serum bilirubin ≤1.5 × ULN. AST and ALT ≤2.5 × ULN.
Cardiac function
QTc interval (corrected by Bazett's formula) ≤470 ms, calculated from three ECG measurements.
Pulmonary Function: FEV1 ≥800 mL. Absolute neutrophil count ≥1.5 × 10⁹/L. Platelet count ≥100 × 10⁹/L. Hemoglobin ≥9.0 g/dL. Renal Function: Calculated creatinine clearance ≥50 mL/min using the Cockcroft-Gault formula. Serum bilirubin ≤1.5 × upper limit of normal (ULN). AST and ALT ≤2.5 × ULN. QTc interval (corrected by Bazett's formula) >470 ms, calculated from three ECG measurements [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06719700 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages